Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
about
The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer.The γ c family of cytokines: fine-tuning signals from IL-2 and IL-21 in the regulation of the immune response.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Immune checkpoint inhibitors: new strategies to checkmate cancer.An increased CD25-positive intestinal regulatory T lymphocyte population is dependent upon Cox-2 activity in the Apcmin/+ model.Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.γ-Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma.CD4 and CD8 T lymphocyte interplay in controlling tumor growth.Unlocking the Complexities of Tumor-Associated Regulatory T Cells.Therapeutic blockade of Foxp3 in experimental breast cancer models.Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells.Regulatory T cells (Tregs): A major immune checkpoint to consider in combinatorial therapeutic HIV-1 vaccines.Anti-CTLA-4 therapy requires an Fc domain for efficacy.Mechanisms of Resistance to PD-1 and PD-L1 Blockade.Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.Genetics and biology of prostate cancerFuture prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance
P2860
Q39338052-E1342CCE-3CC8-480A-AE5F-421F56C38659Q45797119-B9BB9624-2ABE-4B90-9A9B-7506E63E3D8CQ47120629-8EC1BE14-57A0-4257-B0D1-7D74427C5F6EQ47400647-6EAB4CEF-75A4-4D7E-9B71-0FBB5F2C5137Q47757395-8C2789A6-6DC8-45C9-AB2C-127F62D1C362Q47936526-0CDA496F-7157-4F03-B034-0008EFFE61A3Q48164135-EC53F3A5-01F7-4528-842F-A8E8BFA0CB76Q48185876-E90C3164-729D-4304-B3CD-439B39CBB26EQ48293616-ABDB5137-D8C6-4BEA-B69C-209E8C4BBE65Q48325267-7B9B1A14-A675-4E47-8B8D-42A0C644EF57Q49788536-BD84AE50-811A-40E0-8253-3B734DBA8897Q50424105-29C7FC75-E037-43CA-8671-C37F889DEF52Q52629626-88762E3A-753D-4F7D-9603-F3E22721518CQ52707883-C7635B9A-FB27-4EF5-BF48-261BD26BDB1BQ55008075-00255D0D-AFA9-44AC-A5C5-F4BC85459A6AQ55386131-4A7AF9B2-DFCA-4293-9B30-D33054D01A2DQ55473534-1F489743-E332-4EFC-B38E-EDEA211D231AQ57106917-391B11F3-E5A4-4EEE-9CDA-49568B926A70Q57167969-E6C8CAA0-9B54-41AE-881B-EA2E89C304B1
P2860
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Fc-Optimized Anti-CD25 Deplete ...... Eradicate Established Tumors.
@ast
Fc-Optimized Anti-CD25 Deplete ...... Eradicate Established Tumors.
@en
type
label
Fc-Optimized Anti-CD25 Deplete ...... Eradicate Established Tumors.
@ast
Fc-Optimized Anti-CD25 Deplete ...... Eradicate Established Tumors.
@en
prefLabel
Fc-Optimized Anti-CD25 Deplete ...... Eradicate Established Tumors.
@ast
Fc-Optimized Anti-CD25 Deplete ...... Eradicate Established Tumors.
@en
P2093
P2860
P50
P1433
P1476
Fc-Optimized Anti-CD25 Deplete ...... Eradicate Established Tumors.
@en
P2093
Andrew Georgiou
Andrew J S Furness
Anna Sledzinska
Assma Ben Aissa
Ben Challacombe
Dafne Franz
David Nicol
Enrique Miranda Rota
Frederick Arce Vargas
Isabelle Solomon
P2860
P304
P356
10.1016/J.IMMUNI.2017.03.013
P407
P577
2017-04-06T00:00:00Z